Dynavax in flu vaccine deal with Novartis

US firm Dynavax Technologies has announced an agreement with Novartis Vaccines and Diagnostics, a US unit of the Swiss drug major, for the supply, development, and possible commercialization of the former's novel universal influenza vaccine. Under the deal, Novartis will provide Dynavax with a supply of trivalent influenza vaccine, an essential component of its universal influenza vaccine, for both clinical trial use and product sales. Novartis receives an exclusive option to negotiate a joint development and commercialization agreement with Dynavax.

"This agreement with one of the world's leading manufacturers and innovators in influenza vaccines is a fundamental step for the successful development of our universal flu vaccine," said Dino Dina, chief executive of Dynavax, adding: "with this agreement in place we can proceed toward the clinic and to licensure through a known regulatory pathway."

Under the accord, Dynavax will conduct early-stage development through a defined proof-of-concept. If Novartis exercises the right to negotiate a further agreement for development and commercialization, Dynavax would retain co-commercialization rights in the USA and receive product royalties outside of the country. Should the option not be exercised, Novartis remains committed to providing commercial supply of trivalent influenza vaccine with pre-agreed terms and Dynavax retains the right to independently continue with late-stage development and commercialization.